Boston Scientific Acquires Valencia Technologies

Boston Scientific Acquires Axonics, Inc.

November 15, 2024

Medical Devices

Boston Scientific Corporation agreed to and completed the acquisition of Axonics, Inc., a publicly traded medical technology company focused on sacral neuromodulation and urology devices, for $71 per share (approximately $3.7 billion equity value). The deal expands Boston Scientific’s urology portfolio by adding Axonics’ SNM therapy products and related technologies, expected to be accretive to its Urology business over time.

Boston Scientific Acquires Relievant Medsystems, Inc.

September 19, 2023

Medical Devices

Boston Scientific Corporation agreed to acquire Relievant Medsystems, Inc. to expand its neuromodulation portfolio and add the Intracept intraosseous nerve ablation system for vertebrogenic chronic low back pain. The deal includes an $850 million upfront cash payment plus contingent payments tied to sales, and is expected to close in the first half of 2024; Relievant was projected to generate more than $70 million in sales in 2023.

Boston Scientific Acquires Baylis Medical Company Inc.

October 6, 2021

Medical Devices

Boston Scientific Corporation agreed to acquire Baylis Medical Company Inc. for an upfront payment of $1.75 billion, subject to closing adjustments. The acquisition expands Boston Scientific’s electrophysiology and structural heart portfolios by adding Baylis’s RF NRG and VersaCross transseptal platforms and complementary guidewires, sheaths and dilators; Baylis was expected to generate nearly $200 million in net sales in 2022.

Haemonetics Acquires Cardiva Medical

January 20, 2021

Medical Devices

Haemonetics Corporation agreed to acquire Cardiva Medical, Inc., a privately-held maker of vascular closure systems based in Santa Clara, California, for $475 million upfront and up to $35 million in contingent consideration. The acquisition expands Haemonetics' hospital portfolio and its presence in the interventional cardiology and electrophysiology markets and is expected to be accretive to revenue growth.

Boston Scientific Acquires Silk Road Medical for $27.50 per Share

June 18, 2024

Medical Devices

Boston Scientific Corporation agreed to acquire Silk Road Medical, Inc. for $27.50 per share in an all-cash transaction valuing Silk Road's equity at approximately $1.26 billion. The acquisition brings Silk Road's TransCarotid Artery Revascularization (TCAR) platform into Boston Scientific's vascular portfolio to expand treatment options for carotid artery disease and strengthen the company's vascular technology offerings.

Electromedical Products International Acquires Pulvinar Neuro

March 17, 2022

Medical Devices

Electromedical Products International (EPI) has acquired Pulvinar Neuro, a research-oriented medical device company focused on closed-loop neuromodulation and digital therapeutics. The deal expands EPI's scientific and research capabilities to accelerate development and commercialization of Pulvinar's transcranial alternating current stimulation (tACS), individualized feedback stimulation, and cloud-enabled digital therapeutics.